声明
TABLE OF CONTENTS
摘要
ABSTRACT
ABBREVIATIONS
1.INTRODUCTION
2.MATERIALS AND METHODS
2.1 Experimental materials
2.1.1 Main instruments
2.1.2 Cell lines and reagents
2.2 Experimental methods
2.2.1 Cell culture
2.2.2 Experimental groups
2.2.3 Drug preparation
2.2.4 Cell counting
2.2.5 Cell viability
2.2.7 Protein extraction
2.2.8 Protein quantification
2.2.9 Western blotting
2.2.10 Foam cell formation
2.2.11 ELISA
2.2.12 Cell adhesion assay
2.2.13 Measurement of mitochondria ROS
2.2.14 Co-immunoprecipitafion(Co-IP)
2.2.15 Statistical analysis
3.RESULTS
3.2 Ox-LDL increased NLRP3 inflammasome activity
3.3 Ox-LDL increased PARP activity
3.4 Olaparib inhibited Ox-LDL-induced PARP activity
3.5 Olaparib inhibited Ox-LDL-mediated NLRP3 inflammasome activity
3.6 Olaparib inhibited Ox-LDL-mediated increase in IL-1β and IL-18 protein expression and secretion
3.7 Olaparib inhibited Ox-LDL-enhanced foam cell formation
3.8 Olaparib inhibited Ox-LDL-enhanced cell adhesion
3.9 Olaparib-mediated inhibition of NLRP3 inflammasome activation involved in mitochondrial ROS
3.10 Olaparib-mediated NLRP3 inflammasome inhibition was involved in NF-κB activation
3.10.1 Canonical NF-κb activation pathway was involved in olaparib-mediated NLRP3 inflammasome inhibition
3.10.2 Noneanonical NF-κb activation pathway was involved in olaparib-mediated NLRP3 inflammasome inhibition
4.DISCUSSION
5.CONCLUSIONS
REFERENCES
7.LITERATURE REVIEW
ACKNOWLEDGEMENT